Risk Assessment Strategy / Tools & Technology

Topic	Replies	Views	Activity
Carcinogenic Potency Database - Access free With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…	3	2257	August 22, 2022
About the Risk Assessment Strategy / Tools & Technology category	0	633	April 14, 2021
Call to review USP Risk Assessment Review Toolbox	121	3004	July 12, 2025
Excipient Nitrosamine Risk Assessment Tool	0	195	June 30, 2025
CMO Nitrosamine Risk Assessment Drug_Substance_APIs , NDSRI , risk-assessment	7	323	June 27, 2025
How to decide if one anticancer drug is for advanced cancer? risk-assessment	12	540	June 13, 2025
📖 Drug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines-Pub risk-assessment , featured	2	469	May 27, 2025
Can we bypass confirmatory testing of DP based on Theoretical Calc. of NDSRI's	9	1389	April 24, 2025
Nitrosamines in topical products	4	1178	April 15, 2025
NDSRI in finishe products risk-assessment	2	321	March 13, 2025
N-nitrosoamides - a horse of a different color Drug_Substance_APIs	54	6622	March 6, 2025
Risk Assessment and Management Strategy of Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for the Treatment of a Rare Disease- from Prediction to Control-Pub NDSRI	0	490	January 29, 2025
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals	27	3353	January 11, 2025
⚖️ Risk assessment not strong enough, specifically on related impurities containing secondary amine	20	2025	November 28, 2024
📽 Introduction to Using (Q)SAR for the Assessment of Potential Mutagenicity of Drug Impurities QSAR	0	241	October 30, 2024
🖥 Berkeley Madonna Software for Nitrosation Kinetic Calculations	5	782	October 10, 2024
QSAR Toolbox - Free software. Any experience?	18	1920	September 4, 2024
Anybody inquired about Nitrosamines in Poly bags? Packaging	8	1609	August 29, 2024
How much Amine and Nitrating agent "Stoichiometric Ratio" required for formation of Nitrosamine impurities? Drug_Substance_APIs , NDSRI	3	267	August 28, 2024
Regulatory Highlights(OPR&D)	15	2208	August 21, 2024
Sitagliptin NTTP nitrosamine impurity maximum active intake level 37ng to 246.7 ng/per day	29	6306	August 19, 2024
TK6 Cell Line Panel	5	189	July 29, 2024
Background on Purging Factor Calculation for your Risk Assessment	1	644	July 29, 2024
Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies NDSRI	8	1422	July 27, 2024
Useful publications to sharpen your skills for reviewing DS risk assessment	0	341	July 25, 2024
Risk analysis of nitrosamine impurities in liquid products (essences and flavors) Manufacturing , Excipients	3	743	June 28, 2024
A New Framework for Identifying Nitrosamine Risks	1	653	June 13, 2024
Nitrosamine in Azathioprine Drug_Substance_APIs	4	878	May 14, 2024
Nitrosamines Risk in Pharmaceutical Waters	6	2857	May 8, 2024
Risk Analysis for Ergotamine Tartrate Drug_Substance_APIs	4	437	April 22, 2024

Carcinogenic Potency Database - Access free

With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…